Cargando…
Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells
Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272004/ https://www.ncbi.nlm.nih.gov/pubmed/34267927 http://dx.doi.org/10.1002/gch2.202000123 |
_version_ | 1783721124125736960 |
---|---|
author | Dimitriou, Pantelitsa Li, Jin Tornillo, Giusy McCloy, Thomas Barrow, David |
author_facet | Dimitriou, Pantelitsa Li, Jin Tornillo, Giusy McCloy, Thomas Barrow, David |
author_sort | Dimitriou, Pantelitsa |
collection | PubMed |
description | Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the other hand, 3D cultures, including multicellular tumor spheroids (MCTSs), mimic the in vivo cellular arrangement and provide robust platforms for drug testing when grown in hydrogels with characteristics similar to the living body. Microparticles and liposomes are considered smart drug delivery vehicles, are able to target cancerous tissue, and can release entrapped drugs on demand. Microfluidics serve as a high‐throughput tool for reproducible, flexible, and automated production of droplet‐based microscale constructs, tailored to the desired final application. In this review, it is described how natural hydrogels in combination with droplet microfluidics can generate MCTSs, and the use of microfluidics to produce tumor targeting microparticles and liposomes. One of the highlights of the review documents the use of the bottom‐up construction methodologies of synthetic biology for the formation of artificial cellular assemblies, which may additionally incorporate both target cancer cells and prospective drug candidates, as an integrated “droplet incubator” drug assay platform. |
format | Online Article Text |
id | pubmed-8272004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82720042021-07-14 Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells Dimitriou, Pantelitsa Li, Jin Tornillo, Giusy McCloy, Thomas Barrow, David Glob Chall Reviews Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the other hand, 3D cultures, including multicellular tumor spheroids (MCTSs), mimic the in vivo cellular arrangement and provide robust platforms for drug testing when grown in hydrogels with characteristics similar to the living body. Microparticles and liposomes are considered smart drug delivery vehicles, are able to target cancerous tissue, and can release entrapped drugs on demand. Microfluidics serve as a high‐throughput tool for reproducible, flexible, and automated production of droplet‐based microscale constructs, tailored to the desired final application. In this review, it is described how natural hydrogels in combination with droplet microfluidics can generate MCTSs, and the use of microfluidics to produce tumor targeting microparticles and liposomes. One of the highlights of the review documents the use of the bottom‐up construction methodologies of synthetic biology for the formation of artificial cellular assemblies, which may additionally incorporate both target cancer cells and prospective drug candidates, as an integrated “droplet incubator” drug assay platform. John Wiley and Sons Inc. 2021-05-07 /pmc/articles/PMC8272004/ /pubmed/34267927 http://dx.doi.org/10.1002/gch2.202000123 Text en © 2021 The Authors. Global Challenges published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Dimitriou, Pantelitsa Li, Jin Tornillo, Giusy McCloy, Thomas Barrow, David Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells |
title | Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells |
title_full | Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells |
title_fullStr | Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells |
title_full_unstemmed | Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells |
title_short | Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells |
title_sort | droplet microfluidics for tumor drug‐related studies and programmable artificial cells |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272004/ https://www.ncbi.nlm.nih.gov/pubmed/34267927 http://dx.doi.org/10.1002/gch2.202000123 |
work_keys_str_mv | AT dimitrioupantelitsa dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells AT lijin dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells AT tornillogiusy dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells AT mccloythomas dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells AT barrowdavid dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells |